| 초록 |
The ultimate goal of drug research and development is to supply safe and effective pharmaceuticals to patients through non-human and human clinical trials. Innovators have contributed to provide new biological entities for incurable patients or alternate therapy to reduce severe side effects. Recently biosimilar drugs have been highlighted because of lower price but similar efficacy, which would be beneficial to whoever want to save cost in treatment. Regardless of economics projection in bio-industry, research and commercialization should be a common pathway prior to market launch. A few Korean companies have succeeded in global market entry and they use various business models such as incrementally modified drug R&D, research collaboration and co-commercialization with big pharma, selling market authorization, co-founding with global pharma and absorbing platform technology, etc. Core strength in such models is to build an attractiveness of their assets. Many companies are still eager to license out their molecules for global entry, however they want to know what key factors are. In principle there are some considerations in life cycles of product. |
